Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study

被引：0
|
作者：
Savitz, A. [1 ]
Gopal, S. [1 ]
Xu, H. [1 ]
Zhuo, J. [2 ]
Yu, L. [2 ]
Nuamah, I. [1 ]
Wu, C. [2 ]
Hough, D. [1 ]
Mathews, M. [1 ]
Feng, Y. [2 ]
机构：
[1] Janssen Res & Dev, Titusville, NJ USA
[2] Janssen Res & Dev, Beijing, Peoples R China
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2016年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PM419
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [31] PATIENT SATISFACTION WITH 6-MONTHLY VERSUS 3-MONTHLY PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE FOR SCHIZOPHRENIA TREATMENT: RESULTS FROM A PHASE-3, RANDOMISED, NONINFERIORITY STUDY
    Milt, R.
    Desai, P.
    Sanga, P.
    Rozjabek, H.
    Keenan, A.
    Wang, S.
    Pelayo-Teran, J. M.
    Gopal, S.
    VALUE IN HEALTH, 2022, 25 (12) : S402 - S402
  • [32] Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Mathews, Maju
    Soares, Bernardo
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (06) : 499 - 510
  • [33] Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: A multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole
    Ishigooka, Jun
    Nakamura, Jun
    Fujii, Yasuo
    Iwata, Nakao
    Kishimoto, Toshifumi
    Iyo, Masaomi
    Uchimura, Naohisa
    Nishimura, Ryoji
    Shimizu, Naoaki
    SCHIZOPHRENIA RESEARCH, 2015, 161 (2-3) : 421 - 428
  • [34] Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2017, 32 (06) : 329 - 336
  • [35] Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
    Pungor, Katalin
    Bozikas, Vasilis P.
    Emsley, Robin
    Llorca, Pierre-Michel
    Gopal, Srihari
    Mathews, Maju
    Wooller, Annette
    Bergmans, Paul
    THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2020, 10
  • [36] Patient reported outcomes from schizophrenia patients treated with paliperidone palmitate 1-monthly for at least 6 months (picture study)
    Vega, M.
    Arques, S.
    Herrera, B.
    Garcia-Dorado, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S944 - S945
  • [37] Health-Care Utilisation and Costs of Transition from Paliperidone Palmitate 1-Monthly to 3-Monthly Treatment for Schizophrenia: A Real-World, Retrospective, 24-Month Mirror-Image Study
    Chang, Bo-Chieh
    Kuo, Meng-Hsuan
    Lee, Chi-Hui
    Chu, Ya-Lan
    Chen, Kuang-Peng
    Tung, Chun-Liong
    Yang, Ya-Hui
    Hung, Chuan-Sheng
    Tsai, Jui-Hsiu
    Chuang, Hung-Yi
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2024, 20
  • [38] Long term impact of 3-monthly paliperidone palmitate on hospitalisation in patients with schizophrenia: Six-year mirror image study
    Clark, Ivana
    Wallman, Phoebe
    Gee, Siobhan
    Taylor, David
    ACTA PSYCHIATRICA SCANDINAVICA, 2024, 150 (01) : 48 - 50
  • [39] Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study
    Savitz, Adam J.
    Lane, Rosanne
    Nuamah, Isaac
    Gopal, Srihari
    Hough, David
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2015, 54 (02): : 126 - 137
  • [40] Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly? Analysis Based on a Spontaneous Reporting System Database in Japan
    Misawa, Fuminari
    Fujii, Yasuo
    Takeuchi, Hiroyoshi
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (02) : 206 - 207
12345